Abstract
We describe here a model for the study of blood/surface and blood/air interaction as encountered in cardiopulmonary bypass (CPB) circuits. Polyethylene tubing was filled with serum or blood and closed end to end into loops whereby the volume of the remaining air bubble was inversely varied with respect to that of the fluid. The loops were rotated vertically in a water bath at 37°C. The profiles of C3a, iC3, and TCC generation were similar to those observed at surgery, involving CPB. Soluble heparin and heparan sulfate inhibited both C3a and TCC formation, but surface-conjugated heparin had only a minor effect. Binding of C3 and/or C3 fragments to the heparin surface was much reduced compared to the amine matrix to which heparin was linked, but compared with the polyethylene surface the effect was less pronounced. These data suggest that, in addition to the biomaterial surface, the blood-gas interface seems to play an important role in the activation of complement and that this activation is inhibitable by high concentrations of soluble glucose aminoglycans.
Similar content being viewed by others
References
Greeley WJ, Ungerleider RM: Assessing the effect of cardiopulmonary bypass on the brain. Ann Thorac Surg 52:417–419, 1991
Kirklin JK: The postperfusion syndrome.In Cardiopulmonary Bypass: Current Concepts and Controversies, Tinker JH (ed). Philadelphia, W. B.Saunders, 1989, pp 131–147
Oeveren Wv, Kazatchkine MD, Descamps-Latscha B, Haillet F, Fischer E, Carpentier A, Wildevuur CRH: Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation. J Thorac Cardiovasc Surg 89:888–899, 1985
Westaby S: Organ dysfunction after cardiopulmonary bypass. A systemic inflammatory reaction initiated by extracorporeal circuit. Intens Care Med 13:89–95, 1987
Gillinov AM, DeValeria PA, Winkelstein JA, Wilson I, Shaw D, Yeh CG, Rudolph AR, Baumgartner WA, Herskowitz A: Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. Ann Thorac Surg 55:619–624, 1993
Sims PJ, Wiedmer T: The response of human platelets to activated components of the complement system. Immunol Today 12:338–342, 1991
Rinder CS, Rinder HM, Smith BR, Fitch JC, Smith JS, Tracey JB, Matis LA, Squinto SP, Rollins SA: Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 96:1564–1572, 1995
Johnson RJ: Complement activation by biomaterials. Prog Clin Biol Res 337:507–512, 1991
Pekna M, Nilsson L, Nilsson Ekdahl K, Nilsson UR, Nilsson B: Evidence for iC3 generation during cardiopulmonary bypass as the result of blood-gas interaction. Clin Exp Immunol 91:404–409, 1993
Nilsson B, Svensson K-E, Inganäs M, Nilsson UR: A simplified assay for the detection of C3a in human plasma employing a monoclonal antibody raised against denatured C3. J Immunol Methods 107:281–287, 1988
Nilsson UR, Storm K-E, Elwing H, Nilsson B: Conformational epitopes of C3 reflecting its mode of binding to an artificial polymer surface. Mol Immunol 30:211–219, 1993
Pahgburn MK, Müller-Eberhard HJ: Relation of a putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med 152:1102–1114, 1980
Pangburn MK, Schreiber RD, Müller-Eberhard HJ: Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the thioester in native C3. J Exp Med 154:856–867, 1981
Andersson L-O, Barrowcliffe TW, Holmer E, Johnson EA, Sims GEC: Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 9:575–583, 1976
Nilsson L, Storm KE, Thelin S, Bagge L, Hultman J, Thorelius J, Nilsson U: Heparin-coated equipment reduces complement activation during cardiopulmonary bypass in the pig. Artific Organs 14:46–48, 1990
Videm V, Svennevig JL, Fosse E, Semb G, Osterud A, Mollnes TE: Reduced complement activation with heparin-coated oxygenators and tubings in coronary bypass surgery. J Thorac Cardiovasc Surg 113:806–813, 1992
Mollnes TE, Videm V, Götze O, Harboe M, Oppermann M: Formation of C5a during cardiopulmonary bypass: Inhibition by precoating with heparin. Ann Thorac Surg 52:92–97, 1991
Pekna M, Hagman L, Haldén E, Nilsson UR, Nilsson B, Thelin S: Complement activation during cardiopulmonary bypass: Effects of immobilised heparin in a clinical study. Ann Thorac Surg 52:421, 1994
Nilsson Ekdahl K, Nilsson B, Pekna M, Nilsson UR: Generation of iC3 on the interphase between blood and gas. Scand J Immunol 35:85–91, 1992
Mollnes T, Lea T, Frøland SS, Harboe M: Quantification of the terminal complement complex in human plasma by an enzymelinked immunosorbent assay based on monoclonal antibodies against neoantigen on the complex. Scand J Immunol 22:703–710, 1985
Kinoshita T: Biology of complement: The overture. Immunol Today 12:291–295, 1991
Mellbye OJ, Froland SS, Lilleaasen P, Svennevig J-L, Mollnes TE: Complement activation during cardiopulmonary bypass: Comparison between the use of large volumes of plasma and Dextran 70. Eur Surg Res 20:101–109, 1988
Videm V, Fosse E, Mollnes TE, Ellingsen Ø, Pedersen T, Karlsen H: Different oxygenators for cardiopulmonary bypass lead to varying degrees of human complement activation in vitro. J Thorac Cardiovasc Surg 97:764–770, 1989
Bhakdi S, Fassbender W, Hugo F, Carreno M-P, Berstecher C, Malasit P, Kazatchkine MD: Relative inefficiency of terminal complement activation. J Immunol 141:3117–3122, 1988
Hirsh J: Relationship between dose, anticoagulant effect and the clinical efficacy and safety of heparin.In Heparin and Related Polysacharides, Lane DA, Björk I, Lindahl U (eds). New York, Plenum, 1992, pp 283–296
Ekre H-PT, Fjellner B, Hägermark Ö: Inhibition of complement-dependent experimental inflammation in human skin by different heparin fractions. Int J Immunopharmacol 8:277–286, 1986
Maillet F, Kazatchkine MD, Glotz D, Fisher E, Rowe M: Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b. Mol Immunol 20:1401–1404, 1983
Gadd KJ, Reid KBM: The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum. Biochem J 195:471–480, 1981
Law SK, Lichtenberg NA, Levine RP: Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces. J Immunol 123:1388–1394, 1979
Cheung AK, Parker CJ, Janatova J, Brynda E: Modulation of complement activation on hemodialysis membranes by immobilized heparin. J Am Soc Nephrol 2:1328–1337, 1992
Kazatchkine MD, Fearon DT, Metcalfe DD, Rosenberg RD, Austen KF: Structural determinants of the capacity of heparin to inhibit the formation of the human ampliphication C3 convertase. J Clin Invest 67:223–228, 1981
Kazatchkine MD, Fearon DT, Silbert JE, Austen KF: Surfaceassociated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J Exp Med 150:1202–1215, 1979
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gong, J., Larsson, R., Ekdahl, K.N. et al. Tubing loops as a model for cardiopulmonary bypass circuits: Both the biomaterial and the blood-gas phase interfaces induce complement activation in anin vitro model. J Clin Immunol 16, 222–229 (1996). https://doi.org/10.1007/BF01541228
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01541228